Biomarker & Intervention Discovery

Chronic Pancreatitis

This page lists 10 druggable gene targets, 42 approved or trial-tested drug candidates and 15 recent clinical trials for Chronic Pancreatitis, with each agent ranked by the strength of its evidence (clinical, mechanistic or correlative). Candidates include existing drugs that could be repurposed. Sources are linked so you can check every claim.

Plain-language summary → New Treatments for Chronic Pancreatitis (2026)

US DALYs172.3KWHO GHE 2021 · all ages
Global DALYs4.13MWHO GHE 2021 · worldwide
US mortality5,021 deaths/yrWHO GHE 2021
Global mortality115.8K deaths/yrWHO GHE 2021 · worldwide
Spontaneous remissionProgressive exocrine and endocrine insufficiency; spontaneous improvement possible in alcoholic CP with sustained…
Best-intervention remissionAbstinence from alcohol in alcoholic CP: 30-40% pain improvement; endoscopic drainage of ductal obstruction: pain…
Gap sizeLarge — endoscopic therapy and surgery are underused in eligible patients; most are managed with analgesics indefinitely
Primary barrierpractice/access
Full remission profile →
Research Tracker Chronic Disease Interventions Chronic Pancreatitis

Remission & chronicity

Spontaneous remission
Progressive exocrine and endocrine insufficiency; spontaneous improvement possible in alcoholic CP with sustained abstinence (30-40% pain improvement); structural damage (fibrosis, calcifications) is irreversible
Best-intervention remission
Abstinence from alcohol in alcoholic CP: 30-40% pain improvement; endoscopic drainage of ductal obstruction: pain relief in 65-70% at 5 years; total pancreatectomy with islet autotransplantation (TPIAT): 85-90% narcotic independence at 3 years in refractory cases; antioxidant therapy: modest evidence
Gap size
Large — endoscopic therapy and surgery are underused in eligible patients; most are managed with analgesics indefinitely
Primary barrier
practice/access
Pain management in CP often escalates to opioids without adequate trial of endoscopic decompression or TPIAT in eligible patients; TPIAT (total pancreatectomy + islet autotransplantation) for refractory pain is highly effective but available at only ~20 centres in the US; delayed referral is the dominant gap

Biomarker Targets & Therapeutic Agents

Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC. Agents ranked: Clinical > Mechanistic > Correlative.

CFTR 222CPA1 79CTRC 137OPRM1 377PDGFRB 269PRSS1 205SCN9A 280SPINK1 2TGFB1 62TRPV1 187

CFTR

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
NPPB ? unclear Mechanistic DGIdb
LUMACAFTOR ~ modulates Mechanistic DGIdb
TEZACAFTOR ↑ activates Mechanistic DGIdb
SULFONAMIDE-01 ↑ activates Mechanistic DGIdb
SCRIPTAID ? unclear Mechanistic DGIdb
APIGENIN ↑ activates Mechanistic DGIdb
TEZACAFTOR AND IVACAFTOR ? unclear Mechanistic DGIdb
ROFLUMILAST ? unclear Mechanistic DGIdb
CROFELEMER ↓ inhibits Mechanistic DGIdb
UCCF-029 ↑ activates Mechanistic DGIdb
CURCUMIN ? unclear Mechanistic DGIdb
CAPSAICIN ↑ activates Mechanistic DGIdb
IVACAFTOR ↑ activates Mechanistic DGIdb
(R)-BPO-27 ↓ inhibits Mechanistic DGIdb
ICENTICAFTOR ↑ activates Mechanistic DGIdb
BAMOCAFTOR ? unclear Mechanistic DGIdb
UCCF-339 ↑ activates Mechanistic DGIdb
CFTRINH-172 ↓ inhibits Mechanistic DGIdb
NIMODIPINE ↑ activates Mechanistic DGIdb
CYSTEAMINE HYDROCHLORIDE ? unclear Mechanistic DGIdb
PHENYLGLYCINE-01 ↑ activates Mechanistic DGIdb
GLPG2737 ↑ activates Mechanistic DGIdb
GLYH-101 ↓ inhibits Mechanistic DGIdb
IOWH-032 ↓ inhibits Mechanistic DGIdb
OLACAFTOR ~ modulates Mechanistic DGIdb
ABBV-3221 ↑ activates Mechanistic DGIdb
DEUTIVACAFTOR ↑ activates Mechanistic DGIdb
NAVOCAFTOR ~ modulates Mechanistic DGIdb
CBIQ ↑ activates Mechanistic DGIdb
VITAMIN A COMPOUND ? unclear Mechanistic DGIdb
GATX1 ↓ inhibits Mechanistic DGIdb
GLPG-1837 ? unclear Mechanistic DGIdb
FELODIPINE ↑ activates Mechanistic DGIdb
ELEXACAFTOR ~ modulates Mechanistic DGIdb
ENTINOSTAT ? unclear Mechanistic DGIdb
VANZACAFTOR ↑ activates Mechanistic DGIdb
GLPG1837 ↑ activates Mechanistic DGIdb
GALICAFTOR ~ modulates Mechanistic DGIdb
NS004 ↑ activates Mechanistic DGIdb
GLPG-2737 ? unclear Mechanistic DGIdb

Showing top 40 of 222 agents ranked by evidence tier.

CPA1

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
COMPOUND 1B [PMID: 18078750] ↓ inhibits Mechanistic DGIdb
CHEMBL159355 ↓ inhibits Mechanistic 6500.0 nM (Ki) ChEMBL
CHEMBL161705 ↓ inhibits Mechanistic 980.0 nM (Ki) ChEMBL
CHEMBL161702 ↓ inhibits Mechanistic 320.0 nM (Ki) ChEMBL
CHEMBL159616 ↓ inhibits Mechanistic 1160.0 nM (Ki) ChEMBL
CHEMBL161863 ↓ inhibits Mechanistic 1200.0 nM (Ki) ChEMBL
CHEMBL444606 ↓ inhibits Mechanistic 5820.0 nM (Ki) ChEMBL
CHEMBL161819 ↓ inhibits Mechanistic 560.0 nM (Ki) ChEMBL
CHEMBL162465 ↓ inhibits Mechanistic 4950.0 nM (Ki) ChEMBL
CHEMBL161820 ↓ inhibits Mechanistic 5900.0 nM (Ki) ChEMBL
CHEMBL151284 ↓ inhibits Mechanistic 400.0 nM (IC50) ChEMBL
CHEMBL356252 ↓ inhibits Mechanistic 6400.0 nM (IC50) ChEMBL
CHEMBL68399 ↓ inhibits Mechanistic 1400.0 nM (IC50) ChEMBL
CHEMBL33352 ↓ inhibits Mechanistic 1700.0 nM (IC50) ChEMBL
CHEMBL252391 ↓ inhibits Mechanistic 11000.0 nM (Ki) ChEMBL
CHEMBL252009 ↓ inhibits Mechanistic 11000.0 nM (Ki) ChEMBL
CHEMBL251809 ↓ inhibits Mechanistic 4600.0 nM (Ki) ChEMBL
CHEMBL251808 ↓ inhibits Mechanistic 3300.0 nM (Ki) ChEMBL
CHEMBL398771 ↓ inhibits Mechanistic 1900.0 nM (Ki) ChEMBL
CHEMBL254911 ↓ inhibits Mechanistic 16000.0 nM (Ki) ChEMBL
CHEMBL254703 ↓ inhibits Mechanistic 4600.0 nM (Ki) ChEMBL
CHEMBL254495 ↓ inhibits Mechanistic 5000.0 nM (Ki) ChEMBL
CHEMBL254493 ↓ inhibits Mechanistic 1600.0 nM (Ki) ChEMBL
CHEMBL254282 ↓ inhibits Mechanistic 8900.0 nM (Ki) ChEMBL
CHEMBL252003 ↓ inhibits Mechanistic 14000.0 nM (Ki) ChEMBL
CHEMBL251804 ↓ inhibits Mechanistic 2300.0 nM (Ki) ChEMBL
CHEMBL401397 ↓ inhibits Mechanistic 5000.0 nM (Ki) ChEMBL
CHEMBL398545 ↓ inhibits Mechanistic 9900.0 nM (Ki) ChEMBL
CHEMBL253428 ↓ inhibits Mechanistic 7200.0 nM (Ki) ChEMBL
CHEMBL400527 ↓ inhibits Mechanistic 3600.0 nM (Ki) ChEMBL
CHEMBL253224 ↓ inhibits Mechanistic 350.0 nM (Ki) ChEMBL
CHEMBL400526 ↓ inhibits Mechanistic 530.0 nM (Ki) ChEMBL
CHEMBL254900 ↓ inhibits Mechanistic 11000.0 nM (Ki) ChEMBL
CHEMBL401086 ↓ inhibits Mechanistic 35000.0 nM (Ki) ChEMBL
CHEMBL350414 ↓ inhibits Mechanistic 1200.0 nM (Ki) ChEMBL
CHEMBL402987 ↓ inhibits Mechanistic 5000.0 nM (Ki) ChEMBL
CHEMBL272925 ↓ inhibits Mechanistic 32000.0 nM (Ki) ChEMBL
CHEMBL271224 ↓ inhibits Mechanistic 17000.0 nM (Ki) ChEMBL
CHEMBL271223 ↓ inhibits Mechanistic 22000.0 nM (Ki) ChEMBL
CHEMBL271225 ↓ inhibits Mechanistic 11000.0 nM (Ki) ChEMBL

Showing top 40 of 79 agents ranked by evidence tier.

CTRC

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
MILVEXIAN ↓ inhibits Mechanistic DGIdb
COMPOUND 20 [PMID: 12372533] ↓ inhibits Mechanistic DGIdb
CHEMBL457155 ↓ inhibits Mechanistic 70.0 nM (IC50) ChEMBL
CHEMBL323544 ↓ inhibits Mechanistic 70300.0 nM (IC50) ChEMBL
CHEMBL100672 ↓ inhibits Mechanistic 37.0 nM (IC50) ChEMBL
CHEMBL102115 ↓ inhibits Mechanistic 7.0 nM (IC50) ChEMBL
CHEMBL338396 ↓ inhibits Mechanistic 13700.0 nM (Ki) ChEMBL
CHEMBL340276 ↓ inhibits Mechanistic 88000.0 nM (Ki) ChEMBL
CHEMBL263806 ↓ inhibits Mechanistic 12200.0 nM (Ki) ChEMBL
CHEMBL296771 ↓ inhibits Mechanistic 2.4 nM (IC50) ChEMBL
CHEMBL47394 ↓ inhibits Mechanistic 0.69 nM (IC50) ChEMBL
CHEMBL298276 ↓ inhibits Mechanistic 740.0 nM (IC50) ChEMBL
CHEMBL39375 ↓ inhibits Mechanistic 4910.0 nM (Ki) ChEMBL
CHEMBL39086 ↓ inhibits Mechanistic 8400.0 nM (Ki) ChEMBL
CHEMBL1907778 ↓ inhibits Mechanistic 11950.0 nM (Ki) ChEMBL
CHEMBL290025 ↓ inhibits Mechanistic 7550.0 nM (Ki) ChEMBL
CHEMBL22389 ↓ inhibits Mechanistic 48000.0 nM (Ki) ChEMBL
CHEMBL283109 ↓ inhibits Mechanistic 48000.0 nM (Ki) ChEMBL
CHEMBL75703 ↓ inhibits Mechanistic 49000.0 nM (Ki) ChEMBL
CHEMBL107291 ↓ inhibits Mechanistic 6200.0 nM (Ki) ChEMBL
CHEMBL113261 ↓ inhibits Mechanistic 500.0 nM (Ki) ChEMBL
CHEMBL326616 ↓ inhibits Mechanistic 5800.0 nM (Ki) ChEMBL
CHEMBL109852 ↓ inhibits Mechanistic 9600.0 nM (Ki) ChEMBL
CHEMBL11391 ↓ inhibits Mechanistic 55.0 nM (Ki) ChEMBL
CHEMBL432442 ↓ inhibits Mechanistic 720.0 nM (Ki) ChEMBL
CHEMBL286319 ↓ inhibits Mechanistic 1630.0 nM (Ki) ChEMBL
CHYMOSTATIN ↓ inhibits Mechanistic 9.36 nM (Ki) ChEMBL
CHEMBL24211 ↓ inhibits Mechanistic 13700.0 nM (Ki) ChEMBL
CHEMBL26333 ↓ inhibits Mechanistic 295.0 nM (Ki) ChEMBL
CHEMBL284495 ↓ inhibits Mechanistic 1090.0 nM (Ki) ChEMBL
CHEMBL283786 ↓ inhibits Mechanistic 109.0 nM (Ki) ChEMBL
CHEMBL23910 ↓ inhibits Mechanistic 171.0 nM (Ki) ChEMBL
CHEMBL24670 ↓ inhibits Mechanistic 3280.0 nM (Ki) ChEMBL
CHEMBL280377 ↓ inhibits Mechanistic 455.0 nM (Ki) ChEMBL
CHEMBL26182 ↓ inhibits Mechanistic 147.0 nM (Ki) ChEMBL
CHEMBL284017 ↓ inhibits Mechanistic 177.0 nM (Ki) ChEMBL
CHEMBL418568 ↓ inhibits Mechanistic 27800.0 nM (Ki) ChEMBL
CHEMBL26448 ↓ inhibits Mechanistic 3220.0 nM (Ki) ChEMBL
CHEMBL442146 ↓ inhibits Mechanistic 1830.0 nM (Ki) ChEMBL
CHEMBL24071 ↓ inhibits Mechanistic 1430.0 nM (Ki) ChEMBL

Showing top 40 of 137 agents ranked by evidence tier.

OPRM1

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
AXOMADOL ↑ activates Mechanistic DGIdb
BMS-986121 ~ modulates Mechanistic DGIdb
DEXTROAMPHETAMINE SULFATE ? unclear Mechanistic DGIdb
METHADONE HYDROCHLORIDE ↑ activates Mechanistic DGIdb
HYDROCODONE POLISTIREX ↑ activates Mechanistic DGIdb
CHEMBL:CHEMBL570176 ? unclear Mechanistic DGIdb
OXYCODONE HYDROCHLORIDE ↑ activates Mechanistic DGIdb
BEVENOPRAN ↓ inhibits Mechanistic DGIdb
EG-1-230 ↑ activates Mechanistic DGIdb
TAPENTADOL ↑ activates Mechanistic DGIdb
BUTORPHANOL ↑ activates Mechanistic DGIdb
CTOP ↓ inhibits Mechanistic DGIdb
NAVACAPRANT ↓ inhibits Mechanistic DGIdb
NALOXONE HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
CODEINE POLISTIREX ↑ activates Mechanistic DGIdb
LOPERAMIDE ↑ activates Mechanistic DGIdb
ANILERIDINE ? unclear Mechanistic DGIdb
LOFENTANIL ↑ activates Mechanistic DGIdb
LEVOMETHADYL ACETATE HYDROCHLORIDE ↑ activates Mechanistic DGIdb
DEZOCINE ↑ activates Mechanistic DGIdb
FENTANYL HYDROCHLORIDE ↑ activates Mechanistic DGIdb
QUADAZOCINE ↓ inhibits Mechanistic DGIdb
OXYMORPHONE ? unclear Mechanistic DGIdb
NALDEMEDINE TOSYLATE ↓ inhibits Mechanistic DGIdb
ALFENTANIL HYDROCHLORIDE ↑ activates Mechanistic DGIdb
ANTICONVULSANT AGENT ? unclear Mechanistic DGIdb
FENTANYL CITRATE ↑ activates Mechanistic DGIdb
NALTREXONE ↓ inhibits Mechanistic DGIdb
NALMEFENE ↓ inhibits Mechanistic DGIdb
REMIFENTANIL HYDROCHLORIDE ? unclear Mechanistic DGIdb
OXYCODONE ↑ activates Mechanistic DGIdb
NALTRIBEN ↓ inhibits Mechanistic DGIdb
PAREGORIC ↑ activates Mechanistic DGIdb
OXYMORPHONE HYDROCHLORIDE ↑ activates Mechanistic DGIdb
ATOXIFENT ↑ activates Mechanistic DGIdb
DYNORPHIN A ↑ activates Mechanistic DGIdb
ERGOT ALKALOIDS ? unclear Mechanistic DGIdb
ALVIMOPAN ANHYDROUS ↓ inhibits Mechanistic DGIdb
METHYLSAMIDORPHAN ↓ inhibits Mechanistic DGIdb
DYNORPHIN A-(1-13) ↑ activates Mechanistic DGIdb

Showing top 40 of 377 agents ranked by evidence tier.

PDGFRB

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
TELATINIB ↓ inhibits Mechanistic DGIdb
RIPRETINIB ? unclear Mechanistic DGIdb
DOVITINIB ↓ inhibits Mechanistic DGIdb
DASATINIB ANHYDROUS ↓ inhibits Mechanistic DGIdb
LINIFANIB ↓ inhibits Mechanistic DGIdb
ROMIPLOSTIM ? unclear Mechanistic DGIdb
IMATINIB ↓ inhibits Mechanistic DGIdb
SORAFENIB ↓ inhibits Mechanistic DGIdb
AMUVATINIB ↓ inhibits Mechanistic DGIdb
SUNITINIB ↓ inhibits Mechanistic 2.0 nM (IC50) DGIdb
SNS-314 ? unclear Mechanistic DGIdb
PP2 ? unclear Mechanistic DGIdb
TAK-593 ↓ inhibits Mechanistic DGIdb
AXITINIB ↓ inhibits Mechanistic DGIdb
SERALUTINIB ↓ inhibits Mechanistic DGIdb
RG-1530 ↓ inhibits Mechanistic DGIdb
GTP-14564 ↓ inhibits Mechanistic DGIdb
CENISERTIB ? unclear Mechanistic DGIdb
BECAPLERMIN ↑ activates Mechanistic DGIdb
XL-820 ↓ inhibits Mechanistic DGIdb
VELZATINIB ↓ inhibits Mechanistic DGIdb
TANDUTINIB ↓ inhibits Mechanistic 26.0 nM (IC50) DGIdb
HESPERADIN ↓ inhibits Mechanistic DGIdb
FAMITINIB ↓ inhibits Mechanistic DGIdb
REGORAFENIB ↓ inhibits Mechanistic DGIdb
IMATINIB MESYLATE ↓ inhibits Mechanistic DGIdb
X-82 ↓ inhibits Mechanistic DGIdb
TAK-632 ↓ inhibits Mechanistic DGIdb
FLUMBATINIB ↓ inhibits Mechanistic DGIdb
MOTESANIB ↓ inhibits Mechanistic DGIdb
TAMATINIB ? unclear Mechanistic DGIdb
LEUCOVORIN CALCIUM ? unclear Mechanistic DGIdb
TG100-801 ↓ inhibits Mechanistic DGIdb
TOCERANIB PHOSPHATE ↓ inhibits Mechanistic DGIdb
ORANTINIB ↓ inhibits Mechanistic 60.0 nM (IC50) DGIdb
VATALANIB ↓ inhibits Mechanistic DGIdb
CEDIRANIB ↓ inhibits Mechanistic DGIdb
ENMD-981693 ↓ inhibits Mechanistic DGIdb
IACS-9439 ↓ inhibits Mechanistic DGIdb
RINUCUMAB ↓ inhibits Mechanistic DGIdb

Showing top 40 of 269 agents ranked by evidence tier.

PRSS1

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
CYANOPEPTOLIN S ? unclear Mechanistic DGIdb
CYANOPEPTOLIN SS ? unclear Mechanistic DGIdb
COMPOUND 9 [PMID: 3514912] ↓ inhibits Mechanistic DGIdb
ALPHA-1-PROTEINASE INHIBITOR HUMAN ? unclear Mechanistic DGIdb
MELAGATRAN ? unclear Mechanistic DGIdb
NAFAMOSTAT ↓ inhibits Mechanistic DGIdb
CAMOSTAT ↓ inhibits Mechanistic DGIdb
ULINASTATIN ? unclear Mechanistic DGIdb
BORTEZOMIB ? unclear Mechanistic DGIdb
CHEMBL117716 ↓ inhibits Mechanistic 59.2 nM (IC50) ChEMBL
CHEMBL117721 ↓ inhibits Mechanistic 152.0 nM (IC50) ChEMBL
CHEMBL331807 ↓ inhibits Mechanistic 26.6 nM (IC50) ChEMBL
CHEMBL323642 ↓ inhibits Mechanistic 223.0 nM (IC50) ChEMBL
CHEMBL47481 ↓ inhibits Mechanistic 16000.0 nM (Ki) ChEMBL
CHEMBL324485 ↓ inhibits Mechanistic 20.38 nM (IC50) ChEMBL
CHEMBL117678 ↓ inhibits Mechanistic 561.0 nM (IC50) ChEMBL
CHEMBL420322 ↓ inhibits Mechanistic 324.0 nM (IC50) ChEMBL
CHEMBL116245 ↓ inhibits Mechanistic 30.0 nM (IC50) ChEMBL
CHEMBL115902 ↓ inhibits Mechanistic 111.0 nM (IC50) ChEMBL
CHEMBL419222 ↓ inhibits Mechanistic 74.5 nM (IC50) ChEMBL
CHEMBL420688 ↓ inhibits Mechanistic 166.0 nM (IC50) ChEMBL
CHEMBL47543 ↓ inhibits Mechanistic 77000.0 nM (Ki) ChEMBL
CHEMBL117656 ↓ inhibits Mechanistic 160.0 nM (IC50) ChEMBL
CHEMBL117092 ↓ inhibits Mechanistic 97.8 nM (IC50) ChEMBL
CHEMBL325869 ↓ inhibits Mechanistic 4.21 nM (IC50) ChEMBL
CHEMBL115707 ↓ inhibits Mechanistic 40.3 nM (IC50) ChEMBL
CHEMBL117672 ↓ inhibits Mechanistic 75.0 nM (IC50) ChEMBL
CHEMBL47486 ↓ inhibits Mechanistic 77000.0 nM (Ki) ChEMBL
CHEMBL47102 ↓ inhibits Mechanistic 2300.0 nM (IC50) ChEMBL
CHEMBL46845 ↓ inhibits Mechanistic 30.0 nM (IC50) ChEMBL
CHEMBL101030 ↓ inhibits Mechanistic 0.6 nM (IC50) ChEMBL
CHEMBL162443 ↓ inhibits Mechanistic 31.0 nM (IC50) ChEMBL
CHEMBL44891 ↓ inhibits Mechanistic 8400.0 nM (IC50) ChEMBL
CHEMBL102081 ↓ inhibits Mechanistic 2.0 nM (IC50) ChEMBL
CHEMBL341187 ↓ inhibits Mechanistic 990.0 nM (IC50) ChEMBL
CHEMBL457155 ↓ inhibits Mechanistic 70.0 nM (IC50) ChEMBL
CHEMBL164418 ↓ inhibits Mechanistic 158.0 nM (IC50) ChEMBL
CHEMBL435448 ↓ inhibits Mechanistic 240.0 nM (IC50) ChEMBL
CHEMBL163482 ↓ inhibits Mechanistic 211.0 nM (IC50) ChEMBL
CHEMBL130420 ↓ inhibits Mechanistic 13000.0 nM (IC50) ChEMBL

Showing top 40 of 205 agents ranked by evidence tier.

SCN9A

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
TETRODOTOXIN ↓ inhibits Mechanistic DGIdb
XEN403 ↓ inhibits Mechanistic DGIdb
IRAMPANEL ↓ inhibits Mechanistic DGIdb
XEN907 ↓ inhibits Mechanistic DGIdb
N-ME-AMINOPYRIMIDINONE 9 ↓ inhibits Mechanistic DGIdb
PF‐06526290 ↓ inhibits Mechanistic DGIdb
QUINIDINE POLYGALACTURONATE ↓ inhibits Mechanistic DGIdb
VIXOTRIGINE ↓ inhibits Mechanistic DGIdb
LIDOCAINE ↓ inhibits Mechanistic DGIdb
FUNAPIDE ↓ inhibits Mechanistic DGIdb
CD2+ ↓ inhibits Mechanistic DGIdb
PHENYTOIN SODIUM ↓ inhibits Mechanistic DGIdb
HEXYLCAINE HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
ESLICARBAZEPINE ACETATE ↓ inhibits Mechanistic DGIdb
DICHLOROBENZYL ALCOHOL ↓ inhibits Mechanistic DGIdb
PROPOFOL ? unclear Mechanistic DGIdb
OXCARBAZEPINE ↓ inhibits Mechanistic DGIdb
ORPHENADRINE CITRATE ↓ inhibits Mechanistic DGIdb
NERISPIRDINE ↓ inhibits Mechanistic DGIdb
CHLOROPROCAINE HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
MEPHENYTOIN ↓ inhibits Mechanistic DGIdb
ANP-230 ↓ inhibits Mechanistic DGIdb
ABBV-318 ↓ inhibits Mechanistic DGIdb
MEPIVACAINE HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
AMOROLFINE ↓ inhibits Mechanistic DGIdb
RUFINAMIDE ↓ inhibits Mechanistic DGIdb
EVENAMIDE ↓ inhibits Mechanistic DGIdb
SAFINAMIDE ? unclear Mechanistic DGIdb
NKTR-171 ↓ inhibits Mechanistic DGIdb
RG6029 ↓ inhibits Mechanistic DGIdb
RALFINAMIDE ↓ inhibits Mechanistic DGIdb
ZONISAMIDE ↓ inhibits Mechanistic DGIdb
BIIB-095 ? unclear Mechanistic DGIdb
RG7893 ↓ inhibits Mechanistic DGIdb
ARTICAINE HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
DISOPYRAMIDE PHOSPHATE ↓ inhibits Mechanistic DGIdb
PROPOXYCAINE HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
TOCAINIDE HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
TETRACAINE HYDROCHLORIDE ↓ inhibits Mechanistic DGIdb
MERETHOXYLLINE PROCAINE ↓ inhibits Mechanistic DGIdb

Showing top 40 of 280 agents ranked by evidence tier.

SPINK1

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
PEGASPARGASE ? unclear Mechanistic DGIdb
ASPARAGINASE ? unclear Mechanistic DGIdb

TGFB1

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
LY-2382770 ↓ inhibits Mechanistic DGIdb
ETOPOSIDE ? unclear Mechanistic DGIdb
BROXURIDINE ? unclear Mechanistic DGIdb
INOSITOL ? unclear Mechanistic DGIdb
D-ALPHA-TOCOPHEROL ? unclear Mechanistic DGIdb
STREPTOZOCIN ? unclear Mechanistic DGIdb
PROTEASOME INHIBITOR ? unclear Mechanistic DGIdb
FRESOLIMUMAB ↓ inhibits Mechanistic DGIdb
THERAPEUTIC ANDROGEN ? unclear Mechanistic DGIdb
GALUNISERTIB ? unclear Mechanistic DGIdb
TOREMIFENE ? unclear Mechanistic DGIdb
TRETINOIN ? unclear Mechanistic DGIdb
BINTRAFUSP ALFA ~ modulates Mechanistic DGIdb
PIRFENIDONE ? unclear Mechanistic DGIdb
DOXORUBICIN HYDROCHLORIDE ? unclear Mechanistic DGIdb
GOSSYPOL ? unclear Mechanistic DGIdb
EMODIN ? unclear Mechanistic DGIdb
IDOXURIDINE ? unclear Mechanistic DGIdb
HYDROCORTISONE BUTYRATE ? unclear Mechanistic DGIdb
CLADRIBINE ? unclear Mechanistic DGIdb
TG-C ? unclear Mechanistic DGIdb
ASPIRIN ? unclear Mechanistic DGIdb
DISITERTIDE ? unclear Mechanistic DGIdb
RAMIPRIL ? unclear Mechanistic DGIdb
ANTISENSE OLIGONUCLEOTIDES ? unclear Mechanistic DGIdb
HEPARAN SULFATE ? unclear Mechanistic DGIdb
TRIAMCINOLONE ? unclear Mechanistic DGIdb
ESTRADIOL VALERATE ? unclear Mechanistic DGIdb
AMIFOSTINE ANHYDROUS ? unclear Mechanistic DGIdb
KEYHOLE LIMPET HEMOCYANIN ? unclear Mechanistic DGIdb
LUSPATERCEPT ↓ inhibits Mechanistic DGIdb
ATENOLOL ? unclear Mechanistic DGIdb
GALLIUM NITRATE ? unclear Mechanistic DGIdb
ANTIOXIDANT ? unclear Mechanistic DGIdb
FENRETINIDE ? unclear Mechanistic DGIdb
GENISTEIN ? unclear Mechanistic DGIdb
RETINOIC ACID AGENT ? unclear Mechanistic DGIdb
OCTREOTIDE ACETATE ? unclear Mechanistic DGIdb
THERAPEUTIC MELATONIN ? unclear Mechanistic DGIdb
TCDD ? unclear Mechanistic DGIdb

Showing top 40 of 62 agents ranked by evidence tier.

TRPV1

UniProt Ensembl DGIdb Open Targets
Therapeutic Agent Effect Direction Evidence Tier Potency Source
RHTX ↑ activates Mechanistic DGIdb
ABT-102 ↓ inhibits Mechanistic DGIdb
ASIVATREP ↓ inhibits Mechanistic DGIdb
BCTC ↓ inhibits Mechanistic DGIdb
MAVATREP ↓ inhibits Mechanistic DGIdb
POLYGODIAL ? unclear Mechanistic DGIdb
ALLICIN ↓ inhibits Mechanistic DGIdb
JTS-653 ↓ inhibits Mechanistic DGIdb
SB452533 ↓ inhibits Mechanistic DGIdb
MR-1817 ↓ inhibits Mechanistic DGIdb
GRC-6211 ↓ inhibits Mechanistic DGIdb
ACETAMINOPHEN ↑ activates Mechanistic DGIdb
DWP05195 ↓ inhibits Mechanistic DGIdb
STREPTOZOCIN ? unclear Mechanistic DGIdb
CAPSAICIN ↑ activates Mechanistic 19.95 nM (EC50) DGIdb
AMG517 ↓ inhibits Mechanistic DGIdb
5S-HETE ↑ activates Mechanistic DGIdb
BENZYL ISOTHIOCYANATE ? unclear Mechanistic DGIdb
MASOPROCOL ? unclear Mechanistic DGIdb
[3H]RESINIFERATOXIN ↑ activates Mechanistic DGIdb
[3H]A778317 ↓ inhibits Mechanistic DGIdb
CAPSAZEPINE ↓ inhibits Mechanistic 120.0 nM (Ki) DGIdb
NABIXIMOLS ? unclear Mechanistic DGIdb
H+ ↑ activates Mechanistic DGIdb
RECOMBINANT TUMOR NECROSIS FACTOR FAMILY PROTEIN ? unclear Mechanistic DGIdb
NADA ↓ inhibits Mechanistic DGIdb
ZUCAPSAICIN ↑ activates Mechanistic DGIdb
SB366791 ↓ inhibits Mechanistic DGIdb
GRC-15300 ? unclear Mechanistic DGIdb
MRS-1477 ~ modulates Mechanistic DGIdb
ANANDAMIDE ↑ activates Mechanistic DGIdb
JNJ17203212 ↓ inhibits Mechanistic DGIdb
LEVODOPA ? unclear Mechanistic DGIdb
INDOMETHACIN ? unclear Mechanistic DGIdb
AZD1386 ↓ inhibits Mechanistic DGIdb
CAMPHOR OIL ↑ activates Mechanistic DGIdb
ISOPROPYL ISOTHIOCYANATE ? unclear Mechanistic DGIdb
VOACANGINE ? unclear Mechanistic DGIdb
FERRUGINENE B ? unclear Mechanistic DGIdb
PHENYLACETYLRINVANIL ↑ activates Mechanistic DGIdb

Showing top 40 of 187 agents ranked by evidence tier.

Clinical Trials

Drug, biologic and supplement trials (treatment or prevention) from ClinicalTrials.gov whose main condition is Chronic Pancreatitis: recruiting, active or completed, most recently updated first. Data retrieved 2026-10-28.

Safety and Efficacy of Mesenchymal Stem Cells Associated With Chronic Pancreatitis Pain Recruiting
NCT06205342 Phase: Early 1 Started: 2024-07-17

This protocol aims to test whether an infusion of allogeneic bone marrow-derived mesenchymal stromal cells (BM-MSCs) can reduce pain associated with chronic pancreatitis (CP) and explore potential mechanisms of MSC action.

Endotherapy and/or Extracorporeal Shockwave Lithotripsy for Painless Chronic Pancreatitis Recruiting
NCT07074379 Phase: N/A Started: 2025-07-21

Chronic pancreatitis (CP) is caused by factors such as genetics and the environment, leading to the destruction of pancreatic tissue, infiltration of inflammatory cells, and progressive fibrosis of the pancreas. As the disease progresses, pancreatic tissue is damaged, resulting in impaired endocrine...

Malabsorption Blood Test (MBT) to Determine Exocrine Pancreatic Function and Related Quality of Life in Chronic Pancreatitis Recruiting
NCT07418593 Phase: 4 Started: 2026-04-20

This project uses the Malabsorption Blood Test (MBT) to identify patients with recurrent acute or chronic pancreatitis who have mild to moderate exocrine pancreatic insufficiency. A subgroup of patients who have response to pancreatic enzyme replacement therapy will enter a randomized, placebo-contr...

Autologous Mesenchymal Stromal Cells and Islet Co-transplantation in TP-IAT Active Not Recruiting
NCT05095532 Phase: 1 Started: 2021-12-01

This is a clinical trial for chronic pancreatitis (CP) patients undergoing total pancreatectomy with islet autotransplantation (TP-IAT). Participants will be randomized to either bone marrow-derived mesenchymal stem cells (MSCs) or control with the standard of care. Participants will be followed for...

A PiLot ClinicaL TrIal of ParicAlcitol for ChroNiC PancrEatitis Active Not Recruiting
NCT05664880 Phase: Early 1 Started: 2023-06-01

The purpose of this pilot study to examine the feasibility and acceptability of paricalcitol in adults with Chronic Pancreatitis (CP).

Novel Cellular Therapy for the Treatment of Pain Associated With Chronic Pancreatitis Recruiting
NCT05925036 Phase: 1 Started: 2024-01-01

The goal of this clinical trial is to test whether adult stem cells, called mesenchymal stem cells (MSCs) collected from the patient's bone marrow can help reduce pain caused by chronic pancreatitis and improve pancreatic function.

A Study on the Changes of Glucose Metabolism and Exocrine Function in Patients With Chronic Pancreatitis Recruiting
NCT07314489 Phase: Early 1 Started: 2025-04-01

This study aims to investigate the impact of pancreatic exocrine insufficiency on the glucose profile and pancreatic and gastrointestinal endocrine hormones in patients with chronic pancreatitis through pancreatic enzyme intervention in a reverse manner. The primary objective is to observe the chang...

Metformin in Post Chronic Pancreatitis Diabetes Mellitus Recruiting
NCT06937294 Phase: 4 Started: 2025-04-28

The goal of this clinical trial is to evaluate the efficacy and safety of metformin in treating patients with post chronic pancreatitis diabetes mellitus (PPDM-C). The main questions it aims to answer are: * What is the efficacy of metformin in glycemic control in patients with PPDM-C? * What is the...

The Effect of Vitamin D Substitution on the Development of Chronic Pancreatitis Completed
NCT02965898 Phase: N/A Started: 2016-09

Acute pancreatitis (AP) may develop to chronic pancreatitis (CP). In Finland, the ethiology is alcohol in about 80% of the cases. Several symptoms lower the quality of life in CP patients, including abdominal pain, exocrine and endocrine pancreatic insufficiency. Recently, the investigators and othe...

Effect of Non-enteric Coated Enzymes Substitution on Pain in Patients With Chronic Pancreatitis Completed
NCT05042284 Phase: N/A Started: 2021-09-01

Pain in CP entails several independent yet overlapping mechanisms including oxidative stress-mediated parenchymal inflammation, pancreatic and central neuropathy and neuroplasticity. Medical modalities for long-term pain management includes antioxidants and neuromodulators. Pancreatic enzymes are al...

Trial of Indomethacin in Chronic Pancreatitis Completed
NCT04207060 Phase: 1/2 Started: 2020-07-15

The researchers are trying to find a way to slow down the progression of chronic pancreatitis (CP) and investigate the possibility of the long term treatment of this disease.

Alpha-1 Antitrypsin (AAT) Enhances Islet Autograft Survival in Patients With Chronic Pancreatitis Completed
NCT02947087 Phase: 1/2 Started: 2017-01-11

Primary objective: To describe and compare the safety and efficacy of treatment with AAT in chronic pancreatitis patients who undergo total pancreatectomy and islet autotransplantation (TP-IAT).

A Dose Ranging Study Evaluating Efficacy and Safety of NI-03 Completed
NCT02693093 Phase: 1/2 Started: 2016-02-24

The purpose of this study is to determine the safety and efficacy of NI-03.

Hydroxychloroquine and Metabolic Outcomes in Patients Undergoing TPAIT Completed
NCT03283566 Phase: 2 Started: 2017-10-03

This will be a pilot, 12-month phase II, open label, randomized, two-arm, single-blinded, placebo-controlled, parallel clinical trial of individuals undergoing TPAIT (Total Pancreatectomy and Autologous Islet Transplantation) for treatment of chronic pancreatitis (CP). The two study arms consist of ...

A Phase IIa Study With Escalating Dose of MS1819-SD Completed
NCT03481803 Phase: 2 Started: 2017-01-27

This is a Phase IIa study sponsored by AzurRx SAS and Syneos Health is a local representative sponsor and involves testing of a new medication for the compensation of exocrine pancreatic insufficiency (EPI) caused by chronic pacreatitis (CP) and/or distal pancreatectomy. The new medication is called...

Agents Found By Disease-Level Search

Searched directly from “Chronic Pancreatitis” via ClinicalTrials.gov interventions and Open Targets' disease→drug data — independent of the 10-gene target panel above. This surfaces agents whose mechanism doesn't route through a curated gene (combination therapies, standard-of-care drugs, targets outside the panel).

42 agents shown (approved or with trial evidence) — 40 not found by the gene-target search above.

CholecalciferolNOT in gene-target list

Unknown · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT01141998 NCT01141998

Lactated ringers solutionNOT in gene-target list

· 2 trials · source: ClinicalTrials.gov
NCT05772234 NCT07202559

computed tomographyNOT in gene-target list

· 2 trials · source: ClinicalTrials.gov
NCT06549725 NCT06699667

Mesenchymal stem cellsNOT in gene-target list

· 2 trials · source: ClinicalTrials.gov
NCT05925036 NCT06205342

triamcinolone

Phase 3 · 2 trials · source: ClinicalTrials.gov, Open Targets
NCT00583271 NCT00658736

CreonNOT in gene-target list

· 2 trials · source: ClinicalTrials.gov
NCT00957151 NCT01154608

Calcium, DietaryNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01141998

UVBNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01141998

encoscopic retrograde cholangio-pancreatography, extracorporeal shock wave lithotripsyNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04628273

histopathological confirmationNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07104864

autologous mesenchymal stromal cellNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02384018

Therapeutic EUSNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04813055

Percutaneous ProceduresNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04813055

non-EUS-based endoscopic proceduresNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04813055

software LipidicaNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06549725

endoscopic ultrasonographyNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06549725

magnetic resonanceNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06549725

laboratory examinationNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06549725

CytoSorbNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05146336

pharmacologic approaches to glycemic treatmentNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05764629

Diagnosis by Artificial Intelligence modelNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07439757

PancreatinNOT in gene-target list

Early Phase 1 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT00705978

SecretinNOT in gene-target list

Phase 1/2 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT02869893

ProglumideNOT in gene-target list

Phase 1/2 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT05551858

Internet-delivered pain self-management (CBT Condition)NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06386224

Soy breadNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02577640

98% dehydrated alcoholNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00583271

ReparixinNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01967888

Blood DrawNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01392027

PioglitazoneNOT in gene-target list

Phase 2 · 1 trial · source: ClinicalTrials.gov, Open Targets
NCT00782795

Internet-based CBT interventionNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT03322644

etanerceptNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02713997

Alpha 1-AntitrypsinNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT02713997

Pancreatic EnzymeNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT05450627

Endoscopic pancreatic duct decompressionNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07810309

Scrambler TherapyNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT07174609

VIOKASE 16NOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT00559052

Celiac Plexus NeurolysisNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04403074

ESWL vs SOPILNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT04158297

Gabapentin prescriptionsNOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT01138124

TEANOT in gene-target list

· 1 trial · source: ClinicalTrials.gov
NCT06721572

Rituximab

· 1 trial · source: ClinicalTrials.gov
NCT01584388

Generated by the Open Source Medicine Foundation Biomarker Pipeline — 2026-10-08. Data sources: DGIdb, Open Targets, ChEMBL, PubMed, ClinicalTrials.gov. Not medical advice.